Alliance for Pandemic Preparedness

August 11, 2020

Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 Years Report of the Randomized Double-Blind and Placebo-Controlled Phase 2 Clinical Trial

Category:

Topic:

  • [pre-print, not peer-reviewed] Zhang et al. conducted a randomized, double-blind, placebo-controlled trial to evaluate the optimal dose, immunogenicity, and safety of a SARS-CoV-2 inactivated whole virion vaccine (CoronaVac), finding that the vaccine demonstrated favorable safety and immunogenicity on both schedules and both dosages. The lower 3 g dose elicited 92.4% seroconversion under a Day 0, 14 schedule and 97.4% under a Day 0, 28 schedule. Most adverse events were mild and the three serious adverse events were determined to be unrelated to the vaccine. 

Zhang et al. (Aug 10, 2020). Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 Years Report of the Randomized Double-Blind and Placebo-Controlled Phase 2 Clinical Trial. Pre-print downloaded Aug 11 from https://doi.org/10.1101/2020.07.31.20161216